• Solid revenue growth with improved Operating EBITDA margin of 20.6%
• Strong Operating Diluted EPS growth of 66.2%
• Merger integration on track with annual synergies of $14.0m+, above initial expectations

Integral Diagnostics Limited (ASX: IDX) today announces its financial results for the half year ended 31 December 2025 (1H FY26). The Group delivered a strong first half result with solid revenue growth at improved margins. Revenue and other income grew 55.6% to $393.5m, while Operating EBITDA increased 75.6% to $81.1m, with the Operating EBITDA margin expanding 230 bps to 20.6%. Operating NPAT grew 154.6% to $22.3m, and Operating diluted EPS increased 66.2% to 5.9 cents. The merger integration with Capitol Health is proceeding to plan, with $14.0m+ of annual synergies realised, significantly exceeding initial expectations of at least $10.0m. The balance sheet remains strong, with net debt to Operating EBITDA reducing to 2.5x. The company has declared a fully franked interim dividend of 3.3 cents per share, up 32.0% from the prior period.

Continued revenue growth is expected, with the FY26 Operating EBITDA margin forecast to be ~21.0%, driven by the ramp-up of new greenfield sites and brownfield investments, scale benefits including increased use of teleradiology and further procurement efficiencies, and supported by further de-regulation of MRIs and the National Lung Cancer Screening Program. Group FY26 replacement and growth capex is expected to be between $45.0m to $55.0m, and the Group Net Debt/EBITDA (pre-AASB16) is projected to continue to trend down in line with the Group's target ratio of 2.5x or less over time.

The company's focus in FY26 and beyond will be to drive organic earnings growth, accelerate the use of teleradiology, digital and AI, drive its ESG strategy, lead through its Values, and complete the IDX and Capitol merger integration, including ongoing realisation of additional synergies, while continuing to evaluate M&A growth opportunities in a consolidating market.